Firm will identify areas for optimal expansion.

Tripos Discovery Research (TDR) will assist Elan Pharmaceuticals in analyzing and enhancing the diversity of its small molecule screening collection.

TDR will perform computational clustering of key subsets and determine optimal areas for expansion. The company also will provide high-throughput quality control analyses of legacy compounds via mass spectrometry.

Applying its computational design and therapeutic medicinal chemistry tools, TDR says that it is able to reduce drug discovery timelines by up to 30%.

Previous articleLilly Facility Expansion Inaugurated in Puerto Rico
Next articleAlnylam Wins $38.6M Contract to Develop RNAi Therapeutics for Hemorrhagic Fever